REGN•benzinga•
Regeneron Reports Phase 2 Results For Two Novel Monoclonal Antibodies Targeting Distinct Domains Of Factor XI; Says There Was Antithrombotic Effect For Each Antibody; Phase 3 Program To Be Initiated In 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 19, 2024 by benzinga